Cryo-Cell (CCEL)

Executive Summary

Cryo-Cell International (OTCQB: CCEL) is a leading family cord blood bank based in Oldsmar, Florida. Founded in 1989, the company processes and stores umbilical cord blood and tissue stem cells for potential future therapeutic use, serving nearly half a million parents across 87 countries. Its core operations are conducted in an AABB-accredited and FDA-registered facility. Beyond its established storage business, Cryo-Cell has a development pipeline focused on regenerative medicine. The company's lead candidate, Cord Tissue Mesenchymal Stromal Cells for Autism Spectrum Disorder, recently completed a Phase 2 clinical trial (NCT04089579) in February 2024, with results pending publication. This trial represents a potential value driver if positive, but the company remains heavily reliant on its core storage services for revenue. As a small-cap OTC stock, Cryo-Cell faces challenges in liquidity and visibility, but its long operational history and global client base provide a stable foundation. The completion of the Phase 2 trial and any subsequent partnership or licensing deals are key near-term catalysts that could significantly impact the company's valuation.

Upcoming Catalysts (preview)

• 2026Publication of Phase 2 Autism Trial Results70% success
• TBDStrategic Partnership or Licensing Agreement30% success